Burns Kelly E, Thévenin Damien
Department of Chemistry, Lehigh University, 6 East Packer Ave, Bethlehem, PA 18015, U.S.A.
Biochem J. 2015 Dec 15;472(3):287-95. doi: 10.1042/BJ20150876. Epub 2015 Sep 30.
Even though abnormal expression of G protein-coupled receptors (GPCRs) and of their ligands is observed in many cancer cells of various origins, only a few anti-cancer compounds directly act on their signalling. One promising approach to modulate their activity consists of targeting the receptor cytoplasmic surfaces interacting with the associated G-proteins using peptides mimicking the intracellular loops of the receptor. Thus, to be fully effective, the peptide mimics must be selectively targeted to the tumour while sparing healthy tissues, translocated across the cell membrane and stay anchored to the cytoplasmic leaflet of the plasma membrane. In the present study, we introduce a novel way to selectively target and inhibit the activity of a GPCR in cancer cells under acidic conditions, such as those found in solid tumours. We find that the conjugation of a peptide fragment derived from the third intracellular loop (i3) of the protease-activated receptor 1 (PAR1) to a peptide that can selectively target tumours solely based on their acidity [pH(Low) Insertion Peptide (pHLIP)], produces a construct capable of effectively down-regulating PAR1 activity in a concentration- and pH-dependent manner and of inducing a potent cytotoxic effect in a panel of cancer cells that is proportional to the relative level of receptor expression at the cell surface. This strategy not only allows for a more selective targeting and specific intracellular delivery than current approaches, but also offers new possibilities for developing novel anti-cancer drugs targeting GPCRs.
尽管在多种起源的许多癌细胞中都观察到了G蛋白偶联受体(GPCRs)及其配体的异常表达,但只有少数抗癌化合物直接作用于它们的信号传导。一种有前景的调节其活性的方法是使用模拟受体细胞内环的肽来靶向与相关G蛋白相互作用的受体细胞质表面。因此,为了充分发挥作用,肽模拟物必须选择性地靶向肿瘤,同时避免损伤健康组织,穿过细胞膜并锚定在质膜的细胞质小叶上。在本研究中,我们介绍了一种在酸性条件下(如实体瘤中发现的酸性条件)选择性靶向并抑制癌细胞中GPCR活性的新方法。我们发现,将源自蛋白酶激活受体1(PAR1)第三细胞内环(i3)的肽片段与一种仅基于肿瘤酸度就能选择性靶向肿瘤的肽[pH(低)插入肽(pHLIP)]结合,会产生一种构建体,该构建体能够以浓度和pH依赖的方式有效下调PAR1活性,并在一组癌细胞中诱导强烈的细胞毒性作用,且这种作用与细胞表面受体表达的相对水平成正比。这种策略不仅比目前的方法具有更具选择性的靶向和特异性的细胞内递送能力,而且为开发靶向GPCR的新型抗癌药物提供了新的可能性。